Core Viewpoint - The company, Jianxin Co., Ltd. (300107.SZ), is expected to report a net loss attributable to shareholders ranging from -29 million to -20 million yuan for 2025, with a net loss of -31 million to -22 million yuan after excluding non-recurring gains and losses [1] Group 1: Financial Performance - The company is experiencing losses due to short-term operational pressures and the need to balance long-term strategic planning [1] - Sales of key products, including dye intermediates, paper chemicals, and pharmaceutical and agricultural intermediates, have decreased compared to the previous year, influenced by weak industry demand and intensified market competition [1] - The prices of major products have also declined to varying degrees compared to last year, leading to a decrease in profit margins [1] Group 2: R&D and Strategic Initiatives - Increased investment in new product development and upgrades to existing products has raised R&D expenses, negatively impacting current profits [1] - The company views the current performance fluctuations as a short-term phenomenon, with R&D investments gradually converting into technological reserves for future product upgrades and market expansion [1] - Future strategies include optimizing operational strategies, accurately seizing market opportunities, leveraging technological advantages to capture market share in niche segments, and implementing reforms to reduce costs and enhance efficiency [1]

Group 1 - The company *ST Zhongji expects a net profit loss of 35 million to 55 million yuan for the year 2025 [1] - The primary reasons for the expected loss include a decline in sales prices and gross profit of its main product, large-pack tomato sauce, compared to the previous year [1] - The company has made provisions for impairment losses on various assets such as inventory, fixed assets, accounts receivable, and other receivables based on prudence principles and accounting standards [1]

2、2025年，预计非经常性损益对净利润的影响金额约为2.9亿元，非经常性损益主要为子公司收到的政 府补助、应收款项减值转回等。3、子公司红色番茄于2025年12月29日与六师国资公司签订了《债务豁 免协议》、12月30日与国恒集团公司签订了《债务豁免协议》，根据协议约定，六师国资公司豁免的债 务金额为4,248万元，国恒集团公司豁免的债务金额为5,752万元。本次债务豁免生效后，减少子公司红 色番茄对六师国资公司及国恒集团公司的其他应付款，相应增加红色番茄资本公积1亿元。 格隆汇1月26日丨*ST中基(000972.SZ)公布，预计2025年营业收入45,000.00万元至55,000.00万元，亏损 5,500.00万元至3,500.00万元，扣非亏损36,000.00万元至31,000.00万元。1、2025年，公司报告期内业绩 变动主要原因为：一是公司报告期内主要产品大包装番茄酱销售价格及毛利较上年同期下降，导致公司 整体净利润为负；二是基于谨慎性原则，根据会计准则，公司对可能发生减值损失的各类资产如存货、 固定资产、应收账款、其他应收款等计提减值准备；综上原因，预计2025年度业绩将面临亏损。 ...

Group 1 - The company, HeShun Electric, forecasts a net profit loss attributable to shareholders of 42 million to 49.2 million yuan for 2025, compared to a loss of 26.7688 million yuan in the same period last year [1] - The primary reasons for the expected loss include intense competition in traditional industries such as power supply, leading to a decline in product sales and gross margins [1] - The company is accelerating the development of new products to explore new business opportunities, resulting in high research and development expenses that negatively impact current profits [1] - The implementation of an equity incentive plan has led to significant share-based payment expenses affecting current profits [1] - The company has also recognized substantial credit impairment losses and asset impairment losses, which further impact current profits [1]

报告期内，公司受市场波动、DRG支付政策改革等行业动态调整影响，营业收入同比下降。公司采取 调整业务结构，实施降本增效等措施并持续改善经营成效，第四季度亏损幅度收窄，但营业收入总规模 尚未能覆盖运营成本和期间费用。 国际医学2025年三季报显示，前三季度公司主营收入29.95亿元，同比下降16.94%；归母净利润-2.94亿 元，同比下降38.45%；扣非净利润-3.12亿元，同比下降41.94%；其中2025年第三季度，公司单季度主 营收入9.61亿元，同比下降18.95%；单季度归母净利润-1.29亿元，同比下降234.24%；单季度扣非净利 润-1.23亿元，同比下降52.03%；负债率68.8%，投资收益2075.86万元，财务费用1.11亿元，毛利率 6.59%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，国际医学发布业绩预告，预计2025年全年扣非后净利润亏损3.2亿元至3.5亿元。 公告中解释本次业绩变动的原因为： ...

Core Viewpoint - The company expects a net profit loss of 42 million to 49.2 million yuan for the year 2025, compared to a loss of 26.7688 million yuan in the same period last year [1] Group 1: Financial Performance - The primary reason for the expected loss in 2025 is intense competition in traditional industries such as power supply, leading to a decline in product sales and gross margins [1] - The company is accelerating the development of new products to explore new business opportunities, resulting in high research and development expenses that negatively impact current profits [1] - The implementation of an equity incentive plan has led to significant share-based payment expenses, further affecting current profits [1] Group 2: Impairment Losses - The company has recognized substantial credit impairment losses and asset impairment losses, which have also adversely impacted current profits [1]

南财智讯1月26日电，兆日科技发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-2200万元—-1500万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为-2300万 元—-1500万元；报告期内，公司利润主要来源于电子支付密码器系统，营业收入与上年度相比变动不 大，业绩亏损有所减少。2025年度归属于上市公司股东的净利润预计同比亏损减少，主要原因是：上年 度受投资项目估值影响，Planetree（原云启基金）公允价值变动损失较大，本年度该基金估值变动不 大。Planetree公允价值变动计入非经常性损益，本年度扣除非经常性损益后的净利润变动不大。预计公 司2025年度非经常性损益金额约为-100万元至100万元之间，主要为收到的政府补助、投资基金公允价 值变动以及购买理财产品的收益。 ...

Core Viewpoint - Huayi Technology (688071.SH) is expected to report a net profit attributable to shareholders of the parent company ranging from -53.5 million to -64 million yuan for the fiscal year 2025, indicating a challenging financial outlook due to increased fixed costs and limited revenue contribution from new capacities [1] Financial Performance - The projected net profit attributable to shareholders after deducting non-recurring gains and losses for 2025 is estimated to be between -56.31 million and -66.81 million yuan [1] - The decline in gross profit year-on-year is attributed to the increased fixed costs, such as depreciation, following the commissioning of testing service laboratories [1] Industry Context - The automotive industry is experiencing intensified competition, which has negatively impacted the company's ability to recover certain receivables as expected [1]

报告期内，预计非经常性损益对公司归属于上市公司股东的净利润的影响约为1500万元，主要为政府补 助和理财收益等项目影响。上年同期，非经常性损益对归属于上市公司股东的净利润的影响金额为- -6.42亿元。 公告中提到，业绩变动的原因主要是由于行业政策与市场环境变化，部分产品的销量或价格下滑，导致 相关利润下降。此外，整体市场供需关系影响了部分中药材品种价格的延续下跌，使得公司的中药材业 务仍处于亏损状态。 近日，振东制药（300158）发布公告称，预计2025年度归母净利润约亏损2.2亿元至2.8亿元，较上年同 期亏损13.29亿元有所改善。 ...

Core Viewpoint - The company,拓新药业, is forecasting a significant increase in losses for the fiscal year 2025, projecting a loss between 54 million to 73 million yuan, which is a substantial increase compared to the previous year's loss of approximately 19.88 million yuan [1]. Financial Performance - For the first three quarters of 2025, the company's operating revenue decreased by 16.64%, with a net loss of approximately 30.16 million yuan, indicating that the fourth quarter of the previous year alone saw losses exceeding the total losses of the first three quarters [1]. - The company has reported consecutive annual losses for two years, with the loss margin increasing significantly [1]. Management Response - In response to the ongoing losses, the company is actively implementing multiple measures aimed at improving operational performance and achieving profitability [1][2]. - The company acknowledges that the decline in overall business performance is primarily due to fluctuations in demand and declining market prices for certain raw material products, which have adversely affected sales revenue and gross margins [2]. - The company is also facing high fixed costs due to the gradual release of new production capacity from completed investment projects, which is putting pressure on current profits [2]. Shareholder Actions - The company's major shareholder, 伊沃斯, has reduced its stake in the company, decreasing its ownership from 29.84% to 27.37% after a series of share reductions totaling 3.12 million shares [3]. - Despite an influx of financing in 2026, the company's financing balance has decreased, falling to 136 million yuan from 144 million yuan, a decline of over 6% [3].